Sign Up
OverviewAPI
Biopharmaceutical companies ArriVent and Sagimet Biosciences announce public offerings, with ArriVent pricing its initial public offering at $18.00 per share, expected to raise $175.0 million, while Sagimet prices its offering at $12.50 per share, expected to raise $112.5 million. Both companies are focused on developing differentiated medicines for cancer treatment, with ArriVent initially focusing on solid tumors and Sagimet developing FASN inhibitors for NASH treatment.

Ask a question